anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The medical record review will be conducted for 3 rounds in months 0, 12, and 24 after the first medical record abstraction. Before the beginning of the study, a sampling list will be created by Amgen by merging lists of oncologists (and their contact information) to be collected from Cegedim, the ESMO, from major cancer centers and oncology clinics in various countries within Europe. In each round of medical record review, potential participating oncologists will be randomly sampled from all identified oncologists. Potential oncologists will be contacted by letter, telephone or email. The oncologists will be introduced to the study, and their eligibility to participate in the study will be assessed using a standardized questionnaire. The number of oncologists sampled per country will be proportional to the number of oncology centers per country. Approximately 50 oncologists will participate in each round of the study. From each eligible participating oncologist, study staff will then obtain approximately 3 or more medical records for patients who have received Vectibix for the treatment of mCRC during the 6-month period prior to the time of contact with the relevant oncologist and are not involved in an experimental clinical trial when treated with Vectibix. A written consent may be obtained from participating patients to access their medical records, depending on local laws. Medical information will be abstracted from the medical records using standardized forms. Such medical information will include the occurrence and timing of treatment with Vectibix and oxaliplatin-containing chemotherapy, diagnosis of mCRC and the occurrence, timing and results of KRAS testing. The oncologist will also be asked to collect information from the pathology laboratory that performed the KRAS mutation test on the patient, using a standardized pathology data extraction form.
FIELD: medicine, infectious diseases. SUBSTANCE: method involves administration of realdiron at acute period of disease in combination with infusion, hormonal and antibacterial therapy. Realdiron is administrated by the following schedule: 2 times per 24 h at interval for 12 h as inhalations at the dose 250 000-500 000 IU per a single inhalation and once per 24 h at the dose 500 000-1 000 000 IU by intramuscular route and depending on the age. Course of treatment with realdiron is 4-6 days. Method ensures to enhance cellular immunity, protect body from cytopathogenic effect of diphtheria microbe and decrease possibility of complications. EFFECT: enhanced effectiveness of treatment. 3 ex
Subjects will be enrolled between 12 months and 3 year post SPK transplant. Blood sample to test Omnigraft will be collected every 3 months, at the time of rejection or when a biopsy is done.
Accidental ingestion or exposure to even one dose of DSUVIA, especially in children, can result in respiratory depression and death due to an overdose of sufentanil.

DSUVIA is for use in adult patients only in a certified medically supervised healthcare setting. Use of DSUVIA outside of this setting can increase the risk of accidental exposure in others for whom it is not prescribed, causing fatal respiratory depression. Discontinue use of DSUVIA prior to discharge or transfer from the certified medically supervised healthcare setting. DSUVIA is not for home or pediatric use.

Following accidental ingestion of DSUVIA, monitor patients for opioid-related adverse events, such as respiratory depression.
Patients on intervention group will receive 4 sessions of motivational interview at least 20 minutes and once a month. Resilience of patients will be evaluated at the beginnig of the study and five months after the beginning of the study.
BACKGROUND: In 2021, nationwide malaria molecular surveillance revealed a high prevalence of a validated artemisinin resistance marker, the kelch13 (k13) Arg561His mutation, in the Kagera region of northwestern Tanzania. We aimed to investigate the efficacy of artemether-lumefantrine and artesunate-amodiaquine and to confirm the presence of artemisinin partial resistance (ART-R) in the Karagwe district of this region.
METHODS: This single-arm, therapeutic efficacy study was carried out at the Bukangara dispensary in the Karagwe district of the Kagera region in northwestern Tanzania. Eligible participants were aged between 6 months and 120 months, had confirmed Plasmodium falciparum asexual parasitaemia, and met other inclusion criteria according to WHO's standard protocol. Participants were enrolled, treated sequentially with either artemether-lumefantrine or artesunate-amodiaquine, and assessed clinically and parasitologically for 28 days as per WHO protocol. Parasitaemia was measured every 8 h until day 3, on day 7, and then during weekly follow-up visits until day 28. Mutations in the k13 gene and extended haplotypes with the mutations were analysed, and comparisons were made with previous samples collected in the same region of Kagera and in Rwanda and southeast Asia. The primary endpoint was PCR-corrected cure rate.
FINDINGS: Between April 29 and Sept 1, 2022, 343 patients were screened, of whom 176 were enrolled: 88 in each treatment group. The PCR-corrected cure rate was 98% (95% CI 91-100) in the artemether-lumefantrine group and 100% (96-100) in the artesunate-amodiaquine group. Persistent parasitaemia on day 3 occurred in 11 (13%) of 88 patients in the artemether-lumefantrine group and 17 (19%) of 88 patients in the artesunate-amodiaquine group. Arg561His mutations on day 0 and parasitaemia on day 3 were reported in eight (9%) of 87 patients in the artemether-lumefantrine group and ten (12%) of 86 patients in the artesunate-amodiaquine group. The median parasite clearance half-life in patients harbouring parasites with Arg561His mutation was 6·1 h in the artemether-lumefantrine group and 6·0 h in the artesunate-amodiaquine group. Parasites with the Arg561His mutation were not similar to those from southeast Asia and Rwanda but had similar haplotypes to parasites reported in the same Tanzanian region of Kagera in 2021.
INTERPRETATION: This study confirms the presence of ART-R in Tanzania, although artemether-lumefantrine and artesunate-amodiaquine showed high efficacy. A context-specific response strategy and vigilance to detect the reduced efficacy of current antimalarial treatments and ART-R in other parts of the country are urgently needed.
FUNDING: The Bill & Melinda Gates Foundation and the US National Institutes of Health.
INTRODUCTION: Potassium ion channels play a crucial role in maintaining cellular electrical stability and are implicated in various epilepsies. Heterozygous pathogenic variants in KCNK4 cause a recognizable neurodevelopmental syndrome with facial dysmorphism, hypertrichosis, epilepsy, intellectual disability (ID), and gingival overgrowth (FHEIG). To date, no more than nine patients with FHEIG have been described worldwide and still little is known about epileptic phenotype in KCNK4-related disease.
METHODS: We identified a novel de novo p.(Gly139Arg) variant in KCNK4 in a patient with drug-resistant nocturnal seizures, mild ID, and dysmorphic features. In silico analyses of the variant strongly suggest a gain-of-function effect. We conducted a retrospective review of previously published cases, focusing on the epileptic features and response to various treatments.
RESULTS: To date, epilepsy has been reported in 8/10 patients with KCNK4-related disease. The mean age of seizure onset was 1.8 years, and the most common seizure type was focal to bilateral tonic-clonic (5/8). Sodium channel blockers and valproate were effective in the majority of patients, but in 3/8 the epilepsy was drug-resistant. Our patient showed improved seizure control after treatment with the carbonic anhydrase inhibitor sulthiame. Interestingly, the patient showed features of peripheral nerve hyperexcitability syndrome, a phenomenon not previously described in potassium channelopathies caused by increased K+ conductance.
CONCLUSION: Gain-of-function variants in KCNK4 cause a spectrum of epilepsies, ranging from benign isolated epilepsy to epileptic encephalopathy, with focal to bilateral tonic-clonic seizures being the most commonly observed. Importantly, a subgroup of patients present with a mild extra-neurological phenotype without characteristic facial dysmorphism or generalized hypertrichosis. This report expands the phenotypic spectrum of KNCK4-associated disease and provides new insights into the clinical heterogeneity of this rare neurodevelopmental syndrome.
Subjects will receive treatment sequence ABC; A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
Diabetic retinopathy (DR), a most common microangiopathy of diabetes, causes vision loss and even blindness. The mechanisms of exosomal lncRNA remain unclear in the development of DR. Here, we first identifed the pro-angiogenic effect of exosomes derived from vitreous humor of proliferative diabetic retinopathy patients, where lncRNA-MIAT was enriched inside. Secondly, lncRNA-MIAT was demonstrated significantly increased in exosomes from high glucose induced human retinal vascular endothelial cell, and can regulate tube formation, migration and proliferation ability to promote angiogenesis in vitro and in vivo. Mechanistically, the pro-angiogenic effect of lncRNA-MIAT was via the lncRNA-MIAT/miR-133a-3p/MMP-X1 axis. The reduced level of lncRNA-MIAT in this axis mitigated the generation of retinal neovascular in mouse model of oxygen-induced retinopathy (OIR), providing crucial evidence for lncRNA-MIAT as a potential clinical target. These findings enhance our understanding of the role of exosomal lncRNA-MIAT in retinal angiogenesis, and propose a promising therapeutic strategy against diabetic retinopathy.
This study reports the toxicity of Pb exposure on systemic inflammation in high-fat-diet (HFD) mice and the potential mechanisms. Results indicated that Pb exacerbated intestinal barrier damage and increased serum levels of lipopolysaccharide (LPS) and diamine oxidase in HFD mice. Elevated LPS activates the colonic and ileal LPS-TLR4 inflammatory signaling pathway and further induces hepatic and adipose inflammatory expression. The 16S rRNA gene sequencing results showed that Pb promoted the abundance of potentially harmful and LPS-producing bacteria such as Coriobacteriaceae_UCG-002, Alloprevotella, and Oscillibacter in the intestines of HFD mice, and their abundance was positively correlated with LPS levels. Additionally, Pb inhibited the abundance of the beneficial bacteria Akkermansia, resulting in lower levels of the metabolite short-chain fatty acids (SCFAs). Meanwhile, Pb inhibited adenosine 5'-monophosphate-activated protein kinase signaling-mediated lipid metabolism pathways, promoting hepatic lipid accumulation. The above results suggest that Pb exacerbates systemic inflammation and lipid disorders in HFD mice by altering the gut microbiota, intestinal barrier, and the mediation of metabolites LPS and SCFAs. Our study provides potential novel mechanisms of human health related to Pb-induced metabolic damage and offers new evidence for a comprehensive assessment of Pb risk.
Techniques disclosed herein relate to learning and applying contextual patient similarities. In various embodiments, a first value for a query entity may be displayed (702) on an interface. The first value may be related to a first context. A first trained similarity function may be selected (704) from a plurality of trained similarity functions. The first trained similarity function may be associated with the first context. The first selected trained similarity function may be applied (706) to a set of features associated with the query entity and respective sets of features associated with a plurality of candidate entities. A set of one or more similar candidate entities may be selected (708) from the plurality of candidate entities based on application of the first trained similarity function. Information associated with the first set of one or more similar candidate entities may be displayed (710) on the interface.
A system of controlling release of a prescription of fenfluramine or a pharmaceutically acceptable salt thereof for the treatment of one or more refractory epilepsy patients. A central controller of the system has a data store and one or more processors for reading and writing data to the data store. The data store comprises a database of patient records, each patient record having a medication authorization field. Wherein the central controller inhibits dispatch of a first prescription based on unsatisfactory results of an initial medical test consisting of a medical examination by a physician, a genetic test, a physiological function test, and a medical imaging test, and inhibits dispatch of subsequent prescriptions based on unsatisfactory results of an echocardiographic imaging test. Also provided are methods in which the subject systems find use. The systems and methods find use in the treatment of severe subtypes of epilepsy or refractory epilepsy, such as Dravet Syndrome.
The invention relates to a method for measuring biological activity of peptide for secernent of insulin. The method of injecting peptide for secernent of insulin into C57/BL/6J chmice is adopted. The effect for promoting secretion of insulin caused by the peptide for secernent of insulin is observed through measuring density of insulin and C peptide in blood at different times. The effect for reducing blood sugar caused by the peptide for secernent of insulin is observed by injection glucose and peptide for secernent of insulin into C57/BL/6J chmice, and through measuring density of blood sugar at different times. With being obtained and bred easily, C57/BL/6J chmice possess features of longer time for tolerating glucose and more obvious effect for promoting secretion of insulin nad reducing blood sugar with said medicine injected than other model animal. Comapring with methods that uses NOD chmice, db/db or ob/ob chmice, diabetes and fatness Zucker rat or diabetes, rhesus, the invented method provides merits of lower cost, easy to implement and more obvious effect.
NEW MATERIAL:4-aminopyridine derivative expressed by formula I or acid- added salt of said derivative (R1 is H, hydroxyl group, lower alkoxy, morpholino or -NH-B, etc.; B is lower alkyl, cycloalkyl or phenyl; R2 and R3 are H, lower alkyl, lower alkylcarbonyl, or the two join and containing N to form azacycloalkyl or morpholino, etc.; R4 and R5 are H, or join to form quinoline ring or 5,6,7,8-tetrahydroquinoline ring together with ring A, with a proviso that for a case of R1, R4 and R5 are equally H, the case that R2 and R3 are equally H, or equally methyl, is excepted. For a case that R1 is H; R4 and R5 join to form quinoline ring together with the ring A, the case that R2 and R3 are equally H or ethyl, is excepted). USE:Useful as a remedy for Alzheimer-type dementia. PREPARATION:A compound expressed by formula II (RA and RB are H, etc.) is reacted with enamine corresponding to the aimed compound to afford the compound expressed by formula I.
This invention uses leaves of Poacynum hendersonii (Hook.F.) Woodson or apocynum venetum Linn as raw material, it utilizes the method of decoction and alcohol sedimentation to remove impurity. After extract is separated by macroporous adsorptive resins, then use polydextran gel LH-20 to purify, obtain isoquercitrin. Compared with the method of traditional silica gel column chromatography, this method has characteristics such as: experiment period is short, dissipation of organic dissolvent is little, yield of produced product is high, and purity coefficient is fine and so on. Isoquercitrin produced by this invention can be provided for medicine research or used as chemistry control article. Through spectrographical identification, isoquercitrin prepared by this invention is ascertained that its structure is meletin-3-O- beta-D-glucopyranose, its purity is determined by purity angle which is less than purity threshold. Purity of this compound is above 99 percent through computation, corresponding to requirement of control article.
Azéol Spray Nasal is a nasal spray. The constituents responsible for achieving the intended action are: Bifidobacterium breve LA 708, extract of cypres Cupressus sempervirens L., extract of Leguminosae Glycyrrhiza glabra L., glycerin and mannitol.
Glioblastoma (GBM) is the most common malignant brain tumor in adults, which remains incurable and often recurs rapidly after initial therapy. While large efforts have been dedicated to uncover genomic/transcriptomic alternations associated with the recurrence of GBMs, the evolutionary trajectories of matched pairs of primary and recurrent (P-R) GBMs remain largely elusive. It remains challenging to identify genes associated with time to relapse (TTR) and construct a stable and effective prognostic model for predicting TTR of primary GBM patients. By integrating RNA-sequencing and genomic data from multiple datasets of patient-matched longitudinal GBMs of isocitrate dehydrogenase wild-type (IDH-wt), here we examined the associations of TTR with heterogeneities between paired P-R GBMs in gene expression profiles, tumor mutation burden (TMB), and microenvironment. Our results revealed a positive correlation between TTR and transcriptomic/genomic differences between paired P-R GBMs, higher percentages of non-mesenchymal-to-mesenchymal transition and mesenchymal subtype for patients with a short TTR than for those with a long TTR, a high correlation between paired P-R GBMs in gene expression profiles and TMB, and a negative correlation between the fitting level of such a paired P-R GBM correlation and TTR. According to these observations, we identified 55 TTR-associated genes and thereby constructed a seven-gene (ZSCAN10, SIGLEC14, GHRHR, TBX15, TAS2R1, CDKL1, and CD101) prognostic model for predicting TTR of primary IDH-wt GBM patients using univariate/multivariate Cox regression analyses. The risk scores estimated by the model were significantly negatively correlated with TTR in the training set and two independent testing sets. The model also segregated IDH-wt GBM patients into two groups with significantly divergent progression-free survival outcomes and showed promising performance for predicting 1-, 2-, and 3-year progression-free survival rates in all training and testing sets. Our findings provide new insights into the molecular understanding of GBM progression at recurrence and potential targets for therapeutic treatments.
The present inventors constructed mammalian cell-infecting virus vectors encoding epitope-linked-β2m and succeeded in large-scale expression of epitope-linked-β2m in mammalian cells. The present invention provides mammalian cell-infecting virus vectors that encode epitope-linked-β2m microglobulin (β2m) and uses thereof. Furthermore, the present invention provides a method for producing an MHC class I/peptide complex using the vector. In particular, a tetramerized MHC class I/peptide complex is useful in detecting epitope-specific CD8-positive T cells. Moreover, the present invention provides cells introduced with the vector. Target cells added with epitope-linked-β2m produced by the vector of the present invention are also provided. These cells were recognized by antigen-specific cytotoxic T lymphocytes (CTL). The vectors of this invention and polypeptides obtained via the expression of the vectors are useful in immunotherapy for infections and cancers, and in the detection and quantification of antigen-specific CTL.
The invention relates to an antiviral medicine, a preparation method thereof, and an application of realgar in preparing the antiviral medicines. The invention belongs to the technical field of traditional Chinese medicines. The invention provides the application of realgar in the preparation of the antiviral medicines. The adopted realgar is realgar nano-grade granules, and the virus is adenoviruses or respiratory syncytial viruses. The antiviral medicines are realgar nano-grade micro-particles. The preparation method comprises steps that: the realgar medicine material is grinded by using a high-energy ball mill, and is subject to a levigating treatment by using double-distilled water; the product is filtered by using a membrane with a specification of 0.8mm, and is processed by using ultrasonic sound for 10min; the product is sterilized by using a micropore filter with a specification of 0.22mm, such that the realgar nano-grade micro-particles are obtained. The invention discloses an antivirus nature of realgar, such that the pharmaceutical application range of the traditional medicine realgar is widened. Also, a novel broad-spectrum antiviral traditional Chinese medicine material is provided for the preparations of adenovirus resisting (DNA virus resisting) and respiratory syncytial virus resisting (RNA virus resisting) medicines. The invention clarified the antiviral action mechanism of realgar.
The invention discloses a methoxypolyethylene glycol-lactic acid block copolymer, whihc is formed by ring-opening polymerization of D, L-lactide and polyethylene glycol monomethyl ether, wherein the weight ratio of polyethylene glycol monomethyl ether to D,L-lactide is 1:0. 55-0.65 or 1:0. 73-0.89 or 1:0. 91-0.99. The invention also provides a preparation method of the block copolymer. The block copolymer can be used as a carrier for the preparation of drug micelle, and the time of the prepared drug micelle with envelopment rate more than 90% after water redissolution reaches 12 h, which meets the actual situation of clinical drug application, so as to meet the clinical requirements.
BACKGROUND: This systematic review compared the efficacy of traditional Chinese medicine (TCM) treatments for outcomes of different stages and labor pain among pregnant women.
METHODS: Eight databases were electronically searched for TCM on labor pain between January 2012 and January 2022. The studies were recorded and screened according to inclusion criteria and subsequently entered in Note Express. The quality of the included studies was evaluated using the Cochrane risk of bias tool, and network meta-analysis was conducted with Stata 16.0. Forest plots and league tables were used to compare different treatment modalities' effect sizes. Additionally, the probabilities of various treatment modalities for each outcome under the cumulative ranking curve were determined. The protocol was registered in PROSPERO (CRD42022336091). This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.
RESULTS: Thirty articles encompassing 3277 participants were included in the network meta-analysis with 9 different treatment modalities. In terms of pain of labor at 30 minutes, acupuncture + autonomic nerve block was the most effective treatment modality. With regard to the 60-minute pain and the first stage of labor, acupressure + acupuncture therapy was most effective.
CONCLUSION: In general, a combined treatment with acupressure and acupuncture is the most effective approach for relieving labor pain and shortening the duration of labor. Based on these data, we intend to explore further clinical TCM therapy for relieving maternal pain.
Halogen contg. polymerizable phosphorus acid organic ester comprises an organic ester of at least one P acid, the organic radical of the ester contg. at least one polymerizable functional gp., and the ester having Cl or Br bonded directly to P.  The compds. are useful in dentistry.  They provide adhesion to dentin and enamel without the need for acid etching.  They can be employed to repair or veneer hard dental tissue or apply orthodontic brackets or crowns to the tissue.